Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2000 1
2007 1
2008 1
2009 1
2011 1
2016 1
2018 4
2019 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials.
Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, Cook-Bolden FE, Dhawan SS, Forsha D, Gold MH, Guenthner S, Kempers SE, Kircik LH, Parish JL, Rendon MI, Rich P, Stein-Gold L, Tyring SK, Weiss RA, Nasir A, Schmitz C, Boodhoo TI, Kaoukhov A, Berk DR. Moore A, et al. Among authors: werschler p. J Drugs Dermatol. 2018 Sep 1;17(9):987-996. J Drugs Dermatol. 2018. PMID: 30235387 Clinical Trial.
Consensus on the Use of Hyaluronic Acid Fillers from the Cohesive Polydensified Matrix Range: Best Practice in Specific Facial Indications.
van Loghem J, Sattler S, Casabona G, Cotofana S, Fabi SG, Goldie K, Gout U, Kerscher M, Lim TS, de Sanctis Pecora C, Sattler G, Trindade de Almeida A, Wanitphakdeedecha R, Werschler P, Pavicic T. van Loghem J, et al. Among authors: werschler p. Clin Cosmet Investig Dermatol. 2021 Sep 8;14:1175-1199. doi: 10.2147/CCID.S311017. eCollection 2021. Clin Cosmet Investig Dermatol. 2021. PMID: 34526796 Free PMC article.
WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials.
Stein-Gold L, Kircik LH, Draelos ZD, Werschler P, DuBois J, Lain E, Baumann L, Goldberg DJ, Kaufman J, Tanghetti EA, Alvandi N, Weng E, Berk DR, Ahluwalia G. Stein-Gold L, et al. Among authors: werschler p. J Am Acad Dermatol. 2018 Jan 31:S0190-9622(18)30147-6. doi: 10.1016/j.jaad.2018.01.028. Online ahead of print. J Am Acad Dermatol. 2018. PMID: 29409915 Free article. Retracted.
Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated With Rosacea: Pooled Analysis of the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials.
Stein-Gold L, Kircik L, Draelos ZD, Werschler P, DuBois J, Lain E, Baumann L, Goldberg D, Kaufman J, Tanghetti E, Ahluwalia G, Alvandi N, Weng E, Berk D. Stein-Gold L, et al. Among authors: werschler p. J Drugs Dermatol. 2018 Nov 1;17(11):1201-1208. J Drugs Dermatol. 2018. PMID: 30500142 Clinical Trial.
13 results